Critical update for the clinical use of L-carnitine analogs in cardiometabolic disorders
| dc.contributor.author | Mingorance, Carmen | |
| dc.contributor.author | Rodríguez-Rodríguez, Rosalía | |
| dc.contributor.author | Justo, María Luisa | |
| dc.contributor.author | Álvarez de Sotomayor, María | |
| dc.contributor.author | Dolores Herrera, María | |
| dc.date.accessioned | 2020-01-03T16:32:40Z | |
| dc.date.available | 2020-01-03T16:32:40Z | |
| dc.date.issued | 2011-03-28 | |
| dc.identifier.citation | Mingorance, Carmen; Rodríguez Rodríguez, Rosalía; Justo, María Luisa [et al.]. Critical update for the clinical use of L-carnitine analogs in cardiometabolic disorders. Vascular Health and Risk Management, 2011, vol. 2011, núm 7, p. 169-176. Disponible en: <https://www.dovepress.com/critical-update-for-the-clinical-use-of-l-carnitine-analogs-in-cardiom-peer-reviewed-article-VHRM>. Fecha de acceso: 3 ene. 2020. DOI: 10.2147/VHRM.S14356. | ca |
| dc.identifier.issn | 1178-2048 | ca |
| dc.identifier.uri | http://hdl.handle.net/20.500.12328/1417 | |
| dc.description.abstract | Acetyl-L-carnitine (ALC) and propionyl-L-carnitine (PLC) are two naturally occurring carnitine derivates formed by carnitine acetyltransferase. The beneficial cardiovascular effects of ALC and PLC have been extensively evaluated in animals and humans during the last 20 years. For instance, many clinical trials have suggested ALC and PLC as potential strategies in the management of peripheral arterial disease, heart and cerebral ischemia, and congestive heart failure. As a result, several experts have already aimed to revise the clinical evidence supporting the therapeutic use of ALC and PLC. On the basis of their conclusions, our aim was a critical review of the effectiveness of ALC and PLC in the treatment of cardiovascular diseases. Type 2 diabetes mellitus is an independent risk factor for the development of cardiovascular disease. Therefore we also describe recent studies that have addressed the emerging use of ALC and PLC amelioration of the insulin resistant state and its related morbidities. | ca |
| dc.format.extent | 8 | ca |
| dc.language.iso | eng | ca |
| dc.publisher | Dove Press | ca |
| dc.relation.ispartof | Vascular Health and Risk Management | ca |
| dc.relation.ispartofseries | 2011;7 | |
| dc.rights | This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms. | ca |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc/3.0/ | |
| dc.subject.other | Sistema cardiovascular--Malalties | ca |
| dc.subject.other | Insulinoresistència | |
| dc.subject.other | Aparato circulatorio--Enfermedades | |
| dc.subject.other | Insulinorresistencia | |
| dc.subject.other | Cardiovascular system--Diseases | |
| dc.subject.other | Insulin resistance | |
| dc.title | Critical update for the clinical use of L-carnitine analogs in cardiometabolic disorders | ca |
| dc.type | info:eu-repo/semantics/article | ca |
| dc.description.version | info:eu-repo/semantics/acceptedVersion | ca |
| dc.embargo.terms | cap | ca |
| dc.subject.udc | 61 | ca |
| dc.identifier.doi | https://dx.doi.org/10.2147/VHRM.S14356 | ca |
Files in this item
This item appears in the following Collection(s)
-
Ciències de la Salut [725]
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc/3.0/
